Delaying generic competition--corporate payoffs and the future of Plavix.
Shuchman
Miriam
M
Department of Psychiatry at the University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA.
D000077144:Clopidogrel; D004345:Drug Industry / Q000191:economics* / Q000331:legislation & jurisprudence* / Q000458:organization & administration; D016568:Drugs, Generic / Q000191:economics*; D004465:Economic Competition / Q000331:legislation & jurisprudence*; D006801:Humans; D007880:Legislation, Drug; D010330:Patents as Topic / Q000331:legislation & jurisprudence*; D010975:Platelet Aggregation Inhibitors / Q000191:economics; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000191:economics; D013997:Time Factors; D014481:United States; D014485:United States Federal Trade Commission
D016568:Drugs, Generic; D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine